{"name":"CureVac","slug":"curevac","ticker":"CVAC","exchange":"NASDAQ","domain":"curevac.com","description":"CureVac is a biopharmaceutical company based in Tübingen, Germany that develops therapies based on messenger RNA (mRNA). With approximately 375 employees in 2018, it was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee.","hq":"Tübingen, Germany","founded":0,"employees":"","ceo":"Alexander Zehnder","sector":"mRNA Therapeutics / Vaccines","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$900M","metrics":{"revenue":110000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"CV09070101 mRNA vaccine patent cliff ($0.00B at risk)","drug":"CV09070101 mRNA vaccine","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"CV8102 patent cliff ($0.00B at risk)","drug":"CV8102","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-06-28","type":"regulatory","headline":"CureVac Announces FDA Clearance for Phase 1 Clinical Trial of CV09070101 mRNA Vaccine","summary":"CureVac announced that the FDA has cleared the company's Investigational New Drug (IND) application for CV09070101 mRNA vaccine, enabling the initiation of a phase 1 clinical trial.","drugName":"CV09070101 mRNA vaccine","sentiment":"positive"},{"date":"2023-09-14","type":"deal","headline":"CureVac Announces Collaboration with GSK to Develop mRNA-Based Influenza Vaccine","summary":"CureVac announced a collaboration with GSK to develop an mRNA-based influenza vaccine, with the goal of creating a vaccine that can be administered via a nasal spray.","drugName":"mRNA-Based Influenza Vaccine","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-19","type":"trial","source":"simplywall.st","summary":"CureVac (CVAC) Valuation Check After Phase 1 Brain Cancer Vaccine Milestone - simplywall.st","headline":"CureVac (CVAC) Valuation Check After Phase 1 Brain Cancer Vaccine Milestone","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9WZ0pwTFZrZ0ExTHpUOVF0d3RGMDhLQ1VvMmlDRkljVm5DaTJZM3Z0cXBMdFZ3WUtvYm1pSC1sd2VFcHFCSG1jZGlxVjNQczUxNHFKSFMwYm1FcVdk?oc=5","date":"2026-01-13","type":"deal","source":"Finimize","summary":"BioNTech’s CureVac Deal Put A Floor Under A Volatile Stock - Finimize","headline":"BioNTech’s CureVac Deal Put A Floor Under A Volatile Stock","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-09","type":"pipeline","source":"simplywall.st","summary":"Does CureVac’s (CVAC) NASDAQ Exit Quietly Recast Its Risk Profile and Equity Story? - simplywall.st","headline":"Does CureVac’s (CVAC) NASDAQ Exit Quietly Recast Its Risk Profile and Equity Story?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1iTEw4UmJiSHg0bFJFSmg4SkRtZ3VxczVsUTQxWHJsMmt5aUplUTNyaDVuLTdmbENFN0JxWnlCQkdPUG42UTdqcjBVRVo1SUEydElvRFN6Wjd4a2s1d1lzUjdzSGNIemlsU0FtX2d4Z0RUeGxB?oc=5","date":"2025-12-18","type":"pipeline","source":"CureVac","summary":"CureVac is now part of the BioNTech Group - CureVac","headline":"CureVac is now part of the BioNTech Group","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-15","type":"pipeline","source":"simplywall.st","summary":"Does CureVac’s 108% Rally Signal a Smarter Opportunity After mRNA Breakthrough News? - simplywall.st","headline":"Does CureVac’s 108% Rally Signal a Smarter Opportunity After mRNA Breakthrough News?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQTnpxeXBxeUF1d2RfSHNjWDJKVXlaZ0NIZk1wU2NjVXNpdHd2U1lJc0NzV3lXbmZOSlA0Q29SMG13YVZBTlZpdUF3Z0lWaHQ0R0xCT3FyZUNzcWszRlNOZGRkTWY3RWRzaXg5RDZ3NUNOelE4X09OUHJ4U1hrSy1VeVRqeVZjUFVMaFliM3g1WDNBUEw5ZVRrT0V4RzNSQmM?oc=5","date":"2025-06-12","type":"deal","source":"MedCity News","summary":"BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute - MedCity News","headline":"BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPN1FvOFdhSTd4WFZpV3VrN1pSdUxKdkNXLTlISElzVHFORXZORHZYNGZ5aThzdERReGhDNDR1Q0NESWl2dmFMVVZmeVp3aTR4YlRfT3hfdElLSmZ3dThoa2F2aXdfYnpWWkpReWJWT0ZORXZodl92VkF5NXJSY2V3TXhiaDRNMk8zY1lPLWNpSTdNbEFQcGx3X09wU0xraE1hMWJ2QVIyUG1FVjE3YV93czZQWHF2M01LNnBlWF9RdkE?oc=5","date":"2025-06-12","type":"deal","source":"Reuters","summary":"BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals - Reuters","headline":"BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQenN4UkU2VzN2MVdOX05OempTM2VmTWpjMEhFQklON1dXTlpIV1FvTkdwR0tZTTI0LXNaTnJWRVNYdzBpWFMxV3dCYmNUb1RKLTFuenVUOE9qV0ZOMThHOHk3ZnRzVXYybU5zVkZNczdEMHROTkctV1A2UUZ5bTBvTjd6UjRYSGwwaW9acHJ4UE9tLTQ1YlRSbThwLXRXVkl5eDdRMjcyOVRrZmdFaXo0RDNIN29fQQ?oc=5","date":"2025-06-12","type":"deal","source":"Investopedia","summary":"COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments - Investopedia","headline":"COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBWWHhhbmEzdlFqM1duMHE0aGl0TVNhMTR4TzhYMEpPdVdxMGZ0VVRkc1J5LW1WSlpCQnVOZ2NnSm5leFdWNEZNYjJoTGY3VThO?oc=5","date":"2021-09-14","type":"pipeline","source":"The Motley Fool","summary":"CureVac - CVAC - Stock Price & News - The Motley Fool","headline":"CureVac - CVAC - Stock Price & News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNLVNSV0l5Rk9ZOFVtQ19iSDBQM0RLOHVka2JyZ1dJOUdzSFRCZktmMEpzTkVWTGgzTWxfYlVnT1EwcEZuYm1MRDNWRk51eWJrQ2VTMkotUFh0TEx2cWQ0anNzeWFJdUhCUkhkZTZDd192aVhLN296cWwxNkpYMVlHTUNPWjB5clFPZ3oyX2ozRXJxbGhoWkZsWlk1QmJfLTd6TjdCN3J6QXVrbm9C?oc=5","date":"2021-06-11","type":"regulatory","source":"Barron's","summary":"Premarket Movers: Vertex Pharm, CureVac, Arrowhead Pharmaceuticals - Barron's","headline":"Premarket Movers: Vertex Pharm, CureVac, Arrowhead Pharmaceuticals - Barron's","sentiment":"neutral"}],"patents":[{"drugName":"CV09070101 mRNA vaccine","drugSlug":"cvhnlc","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"CV8102","drugSlug":"cv8102","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioNTech","Moderna Therapeutics","Pfizer"],"therapeuticFocus":["mRNA Therapeutics","Vaccines"],"financials":null,"yahoo":null}